6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial.
about
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's diseaseThiopurine monitoring in children with inflammatory bowel disease: a systematic reviewReview article: acute severe ulcerative colitis - evidence-based consensus statements.Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease.Thiopurine therapy in inflammatory bowel disease.Optimizing thiopurine therapy in inflammatory bowel disease.The role of thiopurine metabolite monitoring in inflammatory bowel disease.The role and advances of immunomodulator therapy for inflammatory bowel disease.Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.Toxicity and response to thiopurines in patients with inflammatory bowel disease.Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.Machine Learning Algorithms for Objective Remission and Clinical Outcomes with Thiopurines.Measurement of red blood cell 6-thioguanine nucleotide is beneficial in azathioprine maintenance therapy of Chinese Crohn's disease patients.Trend towards dose reduction of azathioprine as monotherapy in inflammatory bowel disease patients: what about for combination therapy?Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?Exploring associations of 6-thioguanine nucleotide levels and other predictive factors with therapeutic response to azathioprine in pediatric patients with IBD using multilevel analysis.Commentary: Individual vs. weight-based dosing of azathioprine in Crohn's disease.Analytical Pitfalls of Therapeutic Drug Monitoring of Thiopurines in Patients With Inflammatory Bowel Disease.External Validation of a Thiopurine Monitoring Algorithm on the SONIC Clinical Trial Dataset.Response to 'The end of the dosage of 6 Thioguanine nucleotides? Not so sure…'.Thiopurine Metabolism in the Era of Combotherapy.Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring
P2860
Q24197676-E2E6F79D-BA25-4B37-B946-04F82B4E4AA9Q26859122-97FC93C8-2E28-487D-8126-0355A34EDC0FQ34528270-2911D852-C236-41FB-8D60-AEFE055045D2Q36175167-83C0CE81-0B69-4342-BD7B-0ADD0FFD1C82Q37570037-D5005250-D7A2-40A3-8F43-7C94C7BEF381Q37798819-92D7F3D9-FF8E-4297-B792-C30C44E6CC31Q37800458-26F2FF2F-93D5-4728-B91C-3EC2F218E0F9Q38200692-57657450-DB04-4F74-9EA1-5C79689656C6Q38237701-07A8FA91-EBE5-472F-BD0A-E0E4FE72702FQ38417177-9A62F300-4E2F-445F-A209-4E667B9684B2Q38443981-CC391F88-DB00-4CA8-9D86-093A17781C75Q38563075-412EE35E-2667-4642-8BB5-1B6ECDF97C72Q38883897-B956A408-CA6F-4C36-90E8-2C880DF9EEE6Q39789323-7F7D97EE-8930-43C4-A43D-6C99031C5728Q42319267-8AEF9D96-F767-4B2C-87E1-CF0936077E50Q42695266-B7590E16-E1AC-4E32-B491-621E1B8704EDQ43699289-38C6A3D2-0258-42D5-B8D2-09C08E390B84Q47187671-2F143A75-C379-4AB4-84C3-1C7A79F60048Q47426181-B98BFE66-D71F-41BA-998F-9FA85DA22A0AQ47714244-D8592BA5-43CB-4159-BC13-65C225DD3E30Q47740532-0A2EB119-547F-4A7D-AC42-1D54D42CAA51Q50691937-5723A4C3-328B-4C73-8DBB-85BD99CA8F91Q57817595-1098B7D1-0E38-4D83-9D41-302A857F22D1
P2860
6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
6-thioguanine nucleotide-adapt ...... mized, controlled, open trial.
@ast
6-thioguanine nucleotide-adapt ...... mized, controlled, open trial.
@en
type
label
6-thioguanine nucleotide-adapt ...... mized, controlled, open trial.
@ast
6-thioguanine nucleotide-adapt ...... mized, controlled, open trial.
@en
prefLabel
6-thioguanine nucleotide-adapt ...... mized, controlled, open trial.
@ast
6-thioguanine nucleotide-adapt ...... mized, controlled, open trial.
@en
P2093
P50
P1433
P1476
6-thioguanine nucleotide-adapt ...... mized, controlled, open trial.
@en
P2093
Andreas Stallmach
Christian von Tirpitz
Christoph Behrens
Ekkehard Schütz
Guido Adler
Hans Herfarth
Maria Shipkova
Max Reinshagen
Michael Oellerich
Nicolas von Ahsen
P304
P356
10.1373/CLINCHEM.2007.086215
P407
P577
2007-05-10T00:00:00Z